FDA approves new DNA-based test to determine blood compatibility
date:Oct 12, 2018
The U.S. Food and Drug Administration today approved ID CORE XT, a molecular-based assay used in blood transfusion medicine to help determine blood compatibility. The assay can be used to determine blood donor and patient non-ABO red blood cell (RBC) types. ID CORE XT is the second molecular assay approved for use in transfusion medicine, and the first to report genotypes as final results.
The approval of the ID CORE XT Test can streamline blood compatibility testing and provides an additional a
1/5 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
07/10 18:52